Dialysis as a Novel Adjuvant Treatment for Malignant Cancers
(2022) In Cancers 14(20).- Abstract
Cancer metabolism is characterized by an increased utilization of fermentable fuels, such as glucose and glutamine, which support cancer cell survival by increasing resistance to both oxidative stress and the inherent immune system in humans. Dialysis has the power to shift the patient from a state dependent on glucose and glutamine to a ketogenic condition (KC) combined with low glutamine levels—thereby forcing ATP production through the Krebs cycle. By the force of dialysis, the cancer cells will be deprived of their preferred fermentable fuels, disrupting major metabolic pathways important for the ability of the cancer cells to survive. Dialysis has the potential to reduce glucose levels below physiological levels, concurrently... (More)
Cancer metabolism is characterized by an increased utilization of fermentable fuels, such as glucose and glutamine, which support cancer cell survival by increasing resistance to both oxidative stress and the inherent immune system in humans. Dialysis has the power to shift the patient from a state dependent on glucose and glutamine to a ketogenic condition (KC) combined with low glutamine levels—thereby forcing ATP production through the Krebs cycle. By the force of dialysis, the cancer cells will be deprived of their preferred fermentable fuels, disrupting major metabolic pathways important for the ability of the cancer cells to survive. Dialysis has the potential to reduce glucose levels below physiological levels, concurrently increase blood ketone body levels and reduce glutamine levels, which may further reinforce the impact of the KC. Importantly, ketones also induce epigenetic changes imposed by histone deacetylates (HDAC) activity (Class I and Class IIa) known to play an important role in cancer metabolism. Thus, dialysis could be an impactful and safe adjuvant treatment, sensitizing cancer cells to traditional cancer treatments (TCTs), potentially making these significantly more efficient.
(Less)
- author
- organization
-
- Renal physiology and peritoneal dialysis (research group)
- LUCC: Lund University Cancer Centre
- Experimental oncology (research group)
- Kidney cancer research group (research group)
- Lund Melanoma Study Group (research group)
- Internal Medicine - Epidemiology (research group)
- EpiHealth: Epidemiology for Health
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cancer, chemotherapies, dialysis, HDAC, immunotherapies, ketone bodies, radiotherapies, redox balance
- in
- Cancers
- volume
- 14
- issue
- 20
- article number
- 5054
- publisher
- MDPI AG
- external identifiers
-
- scopus:85140579528
- pmid:36291840
- ISSN
- 2072-6694
- DOI
- 10.3390/cancers14205054
- language
- English
- LU publication?
- yes
- id
- 336d85c2-3a58-49af-bc6f-3b545e909358
- date added to LUP
- 2022-12-14 12:33:47
- date last changed
- 2024-09-16 01:15:30
@article{336d85c2-3a58-49af-bc6f-3b545e909358, abstract = {{<p>Cancer metabolism is characterized by an increased utilization of fermentable fuels, such as glucose and glutamine, which support cancer cell survival by increasing resistance to both oxidative stress and the inherent immune system in humans. Dialysis has the power to shift the patient from a state dependent on glucose and glutamine to a ketogenic condition (KC) combined with low glutamine levels—thereby forcing ATP production through the Krebs cycle. By the force of dialysis, the cancer cells will be deprived of their preferred fermentable fuels, disrupting major metabolic pathways important for the ability of the cancer cells to survive. Dialysis has the potential to reduce glucose levels below physiological levels, concurrently increase blood ketone body levels and reduce glutamine levels, which may further reinforce the impact of the KC. Importantly, ketones also induce epigenetic changes imposed by histone deacetylates (HDAC) activity (Class I and Class IIa) known to play an important role in cancer metabolism. Thus, dialysis could be an impactful and safe adjuvant treatment, sensitizing cancer cells to traditional cancer treatments (TCTs), potentially making these significantly more efficient.</p>}}, author = {{Hobro, Sture and Nilsson, Anders and Sternby, Jan and Öberg, Carl and Pietras, Kristian and Axelson, Håkan and Carneiro, Ana and Kinhult, Sara and Christensson, Anders and Fors, Jonas and Maciejewski, Steven and Knox, Jason and Forsal, Innas and Källquist, Linda and Roos, Viktoria}}, issn = {{2072-6694}}, keywords = {{cancer; chemotherapies; dialysis; HDAC; immunotherapies; ketone bodies; radiotherapies; redox balance}}, language = {{eng}}, number = {{20}}, publisher = {{MDPI AG}}, series = {{Cancers}}, title = {{Dialysis as a Novel Adjuvant Treatment for Malignant Cancers}}, url = {{http://dx.doi.org/10.3390/cancers14205054}}, doi = {{10.3390/cancers14205054}}, volume = {{14}}, year = {{2022}}, }